AYTU BIOPHARMA, INC
No SEC Form 4 filings for $AYTU in the last 30 days.
See all $AYTU insider activity →AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi
AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. aytu20260624c_8k.htm false 0001385818 0001385818 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 23, 2026 Date of Report (Date of earl
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AYTU (AYTU BIOPHARMA, INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AYTU coverage spans financial news, earnings and corporate actions.
Quarterly results show modest revenue growth and near‑break‑even loss, indicating potential upside if EXXUA scales.
Termination of a material exclusive license likely reduces future royalty/partner economics and may shift distribution strategy for Metadate CD inventory.
Aytu BioPharma reported a quarterly loss that was narrower than expected, with revenue exceeding estimates. The stock experienced a slight decline post-earnings, but the positive revenue surprise may support a recovery or upward movement.
AYTU has been added to the Zacks Strong Sell list, suggesting a bearish sentiment and potential downside in the near term.
Analyst initiation with a bullish note suggests potential positive price movement.
AlphAI scores every news story that mentions AYTU with an AI model for sentiment and relevance, and aggregates insider trades from AYTU BIOPHARMA, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi
2 min readAYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. aytu20260624c_8k.htm false 0001385818 0001385818 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 23, 2026 Date of Report (Date of earl
4 min readAytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readAYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.
3 min readTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Aytu BioPharma, Inc.
3 min read
